Vir Biotechnology, Inc.
VIR· Nasdaq
Released Aug 5, 2026, after the close
10-Q filed Aug 5, 2026, 36 days after period end · 0001628280-26-053549
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $238.95M | $1.21M | $3.08M | $3.80M |
| Net Income | $80.08M | -$110.96M | -$138.38M | -$194.78M |
| EPS Diluted |
Vir Biotechnology, Inc. · CIK 1706431 · Engraved from SEC EDGAR
| $0.47 |
| -$0.80 |
| -$1.02 |
| -$1.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.